LPHN3 and attention-deficit/hyperactivity disorder: A susceptibility and pharmacogenetic study
Bruxel, E.M.; Salatino-Oliveira, A.; Akutagava-Martins, G.C.; Tovo-Rodrigues, L.; Genro, J.P.; Zeni, C.P.; Polanczyk, G.V.; Chazan, R.; Schmitz, M.; Arcos-Burgos, Mauricio (Oscar); Rohde, L.A.; Hutz, M.H.
Latrophilin 3 (LPHN3) is a brain-specific member of the G-protein coupled receptor family associated to both attention-deficit/hyperactivity disorder (ADHD) genetic susceptibility and methylphenidate (MPH) pharmacogenetics. Interactions of LPHN3 variants with variants harbored in the 11q chromosome improve the prediction of ADHD development and medication response. The aim of this study was to evaluate the role of LPHN3 variants in childhood ADHD susceptibility and treatment response in a...[Show more]
|Collections||ANU Research Publications|
|Source:||Genes, Brain and Behavior|
|01_Bruxel_LPHN3_and_2015.pdf||239.04 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.